The Ademi Firm is investigating Semler Scientific (Nasdaq: SMLR) for possible breaches of fiduciary duty and other violations of law in its transaction with Strive.
Shareholders of Semler Scientific will receive 21.05 Class A common shares of Strive equivalent to about $90.52 per share, based on trading prices as of September 19, 2025. Semler Scientific insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Semler Scientific by imposing a significant penalty if Semler Scientific accepts a competing bid. We are investigating the conduct of the Semler Scientific board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
Join this Action